Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel by Lin, H-L et al.
Paclitaxel (taxol) isolated from the bark of Pacific yew tree Taxus
brovifolia, had been reported to be effective against ovarian, breast
and lung cancers in clinical trial (Chabner, 1991; Rowinsky and
Donehower, 1991; Slichenmyer and Von Hoff, 1991; Anonymous,
1997; Belani, 1998). The underlying mechanism is enhancement
of the tubulins and microtubules dynamic equilibrium and stabi-
lized microtubules (Wilson, 1975; Dustin, 1980; Rowinsky et al,
1990). Thus, Paclitaxel-treated cells are arrested at G2/M phase
(Milross et al, 1996). In addition, Paclitaxel-induced apoptosis and
protease activation are common features of Paclitaxel-sensitive
cells (Vikhanskaya et al, 1998).
It is well known that some cancer cells are more resistant to
Paclitaxel treatment than others. Paclitaxel resistance can be sepa-
rated into two types. One is a multidrug resistance (MDR)-related
type (Dumontet et al, 1996) and the other is a non-MDR-related
type. The human MDR1 gene coding for MDR transporter (pgp-
170) belongs to ATP-binding cassette (ABC) transporter super-
family. The MDR1 overexpression has been reported in solid
tumours, including colon cancer, renal carcinoma, hepatoma and
pancreatic carcinoma (Goldstein, 1996). Uptake and/or efflux of
isotope-labelled drugs or rhodamine 123 are frequently used for
functional assay of pgp-170 in tumour cells. It has been found that
the accumulation of chemotherapy agents, including Paclitaxel, or
rhodamine 123 in tumour cells with overexpressed pgp-170 was
significantly reduced as compared to the MDR antagonist-treated
tumour cells (Watt et al, 1990; Chaudhary and Roninson, 1991;
Kiehntopf et al, 1994). The other Paclitaxel resistance type
includes TRAG-1–5 (Paclitaxel resistance-associated gene 1–5)
(Duan et al, 1997), p53 expression (Catherine et al, 1995)
(Vikhanskaya et al, 1998), alteration of b-tubulin isoform
(Dumontet et al, 1996), changes in the level of intracellular
glutathione (Liebmann et al, 1993), or cell growth morphology
(Frankel et al, 1997).
Berberine, an alkaloid isolated from Coptis chinese, Hydrastis
canadensisL., Berberidaceae, has been found to have antibacterial
(Sun et al, 1988) and anti-inflammatory effects. Moreover, the
Coptis chineseis frequently utilized in Chinese herbal medicine.
The mechanism of berberine-induced growth inhibition in tumour
cells is not well understood, but it has been documented that
berberine interacts with DNA to form complex (Jenning and Ridler,
1983; Taira et al, 1994), inhibits DNA, RNA and protein synthesis
in sarcoma S180 cells in vitro (Creasey, 1979). In addition,
berberine has also been found to affect cell cycle progression.
Berberine-treated HL-60 cells had an increased G2/M phase popula-
tion (Kuo et al, 1995). In our previous studies, we have found that
berberine decreased a-fetoprotein secretion (Chi et al, 1994) and up-
regulated pgp-170 expression in hepatoma cells (Lin et al, 1999).
In this study we examined the role of MDR expression on oral,
gastric and colon cancer cells in response to Paclitaxel treatment;
we show that berberine up-regulated the MDR1 expression and
enhanced the efflux ability of this transporter on six cancer cell
lines. In addition, increased MDR1 expression is accompanied
with reduction of Paclitaxel-induced cytotoxicity, cell cycle alter-
ations, apoptosis and morphology changes in cancer cells. These
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results suggest that MDR1 expression is associated with attenua-
tion of Paclitaxel-induced response.
MATERIALS AND METHODS
Cell culture
Human oral cancer cell lines, OC2 (Wong et al, 1990) and KB
(obtained from American Type Culture Collection, ATCC); human
gastric carcinoma cell line, SC-M1 (Jin et al, 1987) and human
colon cancer cell line, COLO 205 (obtained from ATCC) were
cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) medium
supplemented with 10% heat-inactivated fetal bovine serum
(Hyclone, Logan, UT, USA) and 0.01 mg ml–1 gentamycin
(Gibco). A murine colon cell line, CT26, was cultured in
Dulbecco’s modified Eagles medium (DMEM; Gibco) containing
10% heat-inactivated fetal bovine serum (Hyclone), 0.01 mg ml–1
gentamycin, and 0.1 mM non-essential amino acid. Human gastric
carcinoma cell line, NUGC-3 (Sekiguchi et al, 1978) was cultured
in RPMI-1640 and DMEM in a 1:1 ratio supplemented with
L-glutamine (2 mM; Gibco), kanamycin (100 mg ml–1; Gibco) and
10% heat-inactivated fetal bovine serum. The cells were kept in a
humidified incubator with 5% carbon dioxide and 95% air at 37°C.
Drug treatment
Berberine (Sigma; B 3251, St Louis, MO, USA) and Paclitaxel
(Biomol Research Labs, PA, USA) were dissolved in double
distilled water and dimethylsulphoxide (DMSO) respectively. Six
cell lines were treated with berberine (0.32–320 mM) for 24 h. For
some experiments, cells were pretreated with berberine (32 mM)
for 24 h, followed by replacement with fresh medium containing
DMSO (0.1%) or various concentrations of Paclitaxel (0.001,
0.01, 0.1, 1, 10 mM) for an additional 24 h. After drug treatment,
cells were harvested by TEG (0.125% trypsin, 0.05% EDTA,
0.05 g ml–1 glucose) and used for the following assays.
MDR1 transporter expression
The cell pellet (1 ´ 106) was first resuspended in 100 ml phosphate-
buffered saline (PBS), followed by incubation with 20 ml
(12.5 mg ml–1) anti-human MDR1 monoclonal antibody conju-
gated with phycoerythrin (PE) (Immunotech, UIC2 clone) for 15
min at room temperature. Non-specific binding was determined
with an isotype control of mouse PE-conjugated IgG1. After incu-
bation, cells were washed twice with PBS then resuspended in 500
ml PBS for flow cytometic analysis.
Multidrug-resistance protein expression
The cell pellets (1 ´ 106) were added with lysing buffer (0.5%
Triton X-100, 0.2 mg ml–1 Na2EDTA.2H2O, and 1% bovine serum
albumin in PBS) and left on ice for 15 min. The mixture was then
added with 100% methanol pre-cooled to –20°C and centrifuged at
300 g for 5 min. The supernatant was discarded and pellet was
washed with PBS again. For primary antibody staining, the cell
pellets were incubated with 20 ml mouse anti-MRP monoclonal
antibody (1:50 dilution) (Chemicon International Inc., QCRL-3
clone) at 4°C for 30 min. Non-specific binding was determined
using mouse IgG2a antibody. The cells were washed with PBS
followed by incubation with goat anti-mouse antibody conjugated
with fluorescein isothiocyanate (FITC) (1:30 dilution) (Organon
Teknika Co.) at room temperature for 30 min. Finally, cells were
washed with PBS and the multidrug resistance protein (MRP)
expression was examined by flow cytometry.
Functional assay of MDR1 transporter
Previously, it has been reported that the retention of rhodamine 123
correlated well with the function of pgp-170 (Ludescher et al, 1992;
Kiehntopf et al, 1994; Petriz and Garcia-Lopez, 1997; Salvioli et al,
1997). Therefore, retention of rhodamine 123 can be used as an
indicator of pgp-170 function. Cells (2–3 ´ 105) were treated with
0.32, 3.2, 32, 320 mM berberine for 24 h prior to the addition of
10 mg ml–1 rhodamine 123 (Sigma). After incubation at 37°C for
5 min, cells were harvested and centrifuged at 300 g for 10 min.
Cell pellets were resuspended with 500 ml PBS and immediately
used for flow cytometic analysis of rhodamine 123 retention.
MTT viability assay
Cells were cultured in 96-well cell culture cluster (Costar) at a
density of 4 ´ 104 cells ml–1. After drug treatment for 24–72 h,
medium was discarded and replaced with an equal volume
(100 ml) of fresh medium containing MTT (0.456 mg ml–1; 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) for incu-
bation 1.5 h in a 37°C incubator. The medium was discarded and
then 100 ml DMSO were added. Cell viability was determined
according to the colourimetric comparison by reading OD values
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Figure 1 The effect of berberine treatment on MDR1 expression was
examined in two oral cancer cell lines (OC2, KB), two gastric cancer cell lines
(SC-M1, NUGC-3) and two colon cancer cell lines (CT26, COLO 205). Cells
were treated with indicated concentrations of berberine for 24 h followed by
evaluation of MDR1 expression. MDR1 expression is estimated by flow
cytometry. Data were acquired and analysed using FACSCalibur. A detailed
description is in Materials and Methods418 H-L Lin et al
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from microplate reader (Spectra MAX 250) at absorption wave-
length of 570 nm.
Flow cytometric analysis of DNA content
The cell pellets (1 ´ 106) were added with lysing buffer (0.5%
Triton X-100, 0.2 mg ml–1 Na2EDTA.2H2O and 1% bovine serum
albumin in PBS) and left on ice for 15 min. The mixture was then
added with 100% methanol pre-cooled to –20°C and centrifuged at
300 g for 5 min. The supernatant was discarded and pellet was
washed with PBS again. The pellet was stained with DNA staining
solution (50 µg ml–1-propidium iodide, 5 k units ml-1 of RNaseA
for 30 min at 4°C in the dark. The DNA content of each cell was
measured using a Becton Dickinson FACSCalibur flow cytometer.
Flow cytometry
Cells (10 000) were analysed on a Becton Dickinson
FACSCalibur  flow cytometer using an argon-ion laser (15 mWatt)
with incident beam at 488 nm. Green fluorescence (rhodamine 123
or FITC) corresponding to efflux ability of MDR1 transporter or
MRP expression were collected through a 530 nm filter, while the
red fluorescence (PE) representing either the level of MDR1 trans-
porter or DNA content (propidium iodide) was collected through a
585 nm filter. Data were acquired and analysed using
FACS/CellQuest software on a Power Macintosh 7600/120
computer. Apoptotic cells and cells at specific cycle phases were
determined by ModFit LT software.
Morphology changes
To observe the cell morphology, OC2 and SC-M1 cells (2 3 106
cells) were cultured on 75 cm2 cell culture flasks (Corning) and
treated with various doses of the drug. Photograph was taken at
300-fold magnification on an inverted phase-contrast microscope
(Olympus; IMT-2)
Statistical analysis
Statistical anslyses were performed using the Sigmastat software.
Comparisons between the means of various treatment groups were
analysed using Student’s t-test or ANOVA. Tukey test was used
for multiple comparisons. The difference was considered signifi-
cant when P < 0.05.
RESULTS
Figure 1 shows the pgp-170 expression on berberine-treated six
different cancer cell lines (OC2, KB, SC-M1, NUGC-3, CT26 and
COLO 205). The expression of pgp-170 was increased signifi-
cantly in five cell lines (OC2, KB, SC-M1, NUGC-3, COLO 205)
after treatment with 32 mM berberine. No specific binding of pgp-
170 was observed using isotype antibody. The expression of pgp-
170 in CT26 cells was much less than the other five cell lines.
When the berberine dose is increased to 160 mM or 320 mM, a
further increase of pgp-170 expression was observed on OC2 and
CT26 cells respectively. In comparison, no further increase in
levels of pgp-170 was found on 160 mM berberine-treated KB, SC-
M1, NUGC-3 and COLO 205 cells. Table 1 shows that 0.32 and
3.2 mM of berberine had little effect on cell viability. The viability
of OC2, SC-M1 and COLO 205 cells decreased to 72.3–75.2% of
control 24 h after a 32 mM berberine treatment. When the dose of
berberine is increased to 320 mM, the viability further reduced to
17.8–34.4% of control. Since treatment of cells with 32 mM of
berberine resulted in maximal expression of pgp-170 without
significant effect on cell viability, we used 32 mM berberine treat-
ment for further analyses.
Table 1 The effect of berberine treatment on viability of OC2, SC-M1 and
COLO 205 cells
Dose of berberine (mM)
0.32 3.2 32 320
OC2 105.3 ± 9.3 83.3 ± 3.9 75.2 ± 3.4 22.9 ± 7.3
SC-M1 96.6 ± 8.2 90.0 ± 7.6 75.1 ± 9.2 17.8 ± 3.2
COLO 205 97.2 ± 2.2 94.6 ± 5.1 72.3 ± 0.9 34.4 ± 3.2
Cells were treated with berberine or vehicle for 24 h and then used for MTT
assay. Data (mean ± s.e.m.) represent the percentage of medium control
from duplicate samples of three separate experiments.
OC2 KB CT26
A
120
100
80
60
40
20
0
Medium control
Berberine 0.32 mM
Berberine 3.2 mM
Berberine 32 mM
M
e
a
n
 
o
f
 
r
h
o
d
a
m
i
n
e
 
1
2
3
 
f
l
u
o
r
e
s
c
e
n
c
e
120
100
80
60
40
20
0
COLO 205 NUGC3 SC-M1
Medium control
Berberine 0.32 mM
Berberine 3.2 mM
BBerberine 32 mM
B
Figure 2 The effect of berberine on rhodamine 123 retention in six
digestive track cancer cell lines (OC2, KB, SC-M1, NUGC-3, CT26, COLO
205). Cells were treated with berberine (0.32 mM, 3.2 mM, 32 mM) for 24 h prior
to the addition of rhodamine 123. (A) OC2, KB, CT26 cells (B) COLO 205,
NUGC-3, SC-M1 cells. Data are the mean ± SE of duplicate samples from
three independent experiments. *Indicates statistically significant difference
(P < 0.05) as compared to the medium control group using Student’s t-testBerberine-induced MDR1 expression reduced Paclitaxel responses in cancer cells 419
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It had been documented that the efflux of rhodamine 123 corre-
lated well with pgp-170 expression. By this rationale, we used
rhodamine 123 to evaluate whether the pgp-170 that expressed on
cancer cells is functional. Figure 2 shows that two oral cancer cell
lines (OC2, KB) had similar pattern of berberine-induced
response. The efflux of rhodamine 123 showed a decreasing trend
with the elevated dose of berberine. The efflux of rhodamine 123
in two gastric cancer cell lines (SC-M1, NUGC-3) and a colon
cancer cell line (COLO 205) after 32 mM berberine treatment
decreased significantly (P < 0.05) as compared with medium
control. No significant decrease in rhodamine 123 retention was
observed in berberine-treated CT26 cells. This corresponded well
with our observation (Figure 1) that the pgp-170 expression was
not increased in CT26 cells after a 32 mM berberine treatment.
In order to understand whether the enhanced efflux of pgp-170
correlates with drug resistance, we further investigated the effect
of berberine treatment on Paclitaxel-induced response in three cell
lines. Figure 3 shows that no significant decrease in viability of
OC2, and SC-M1 cells was observed after Paclitaxel treatment for
24 h. The viability of COLO 205 cells showed a significant
decrease (P < 0.001) after treatment with 10 nM–10 mM Paclitaxel
for 24 h. No significant difference in viability was observed in
cells treated with Paclitaxel alone and cells pretreated with
berberine then treated with Paclitaxel (P > 0.05). When cancer
cells were treated with 10 nM–10 mM Paclitaxel for 72 h, signifi-
cant (P < 0.05) decreases in viability were observed in three cancer
cell lines. Significantly higher viabilities (P < 0.05) were observed
in berberine pretreatment groups than Paclitaxel (0.01–10 mM)
treatment groups.
Previously, we had reported that low (10 nM) dose of Paclitaxel
induced early apoptosis of SC-M1 cells while high (100 nM) dose
Paclitaxel induced G2/M phase arrest prior to cell death (Chang et
al, 1996). In order to determine whether berberine pretreatment
affected Paclitaxel-induced cycle changes in cancer cells, cells
were pretreated with berberine (32 mM) for 24 h followed by treat-
ment with fresh medium containing low (10 nM) or high (100 nM)
dose of Paclitaxel. Figure 4 shows that the DNA histogram of OC2
cells treated with berberine for 24 h (B 24, BW) had no remark-
able alteration as compared with medium control (C24, C48). Low
and high dose Paclitaxel treatment of OC2 cells resulted in apop-
totic peaks and G2/M arrest respectively. In comparison, there
were no significant changes on cell cycle in low (BL) or high (BH)
dose Paclitaxel treatment of berberine-pretreated OC2 cells, as
compared to vehicle controls (BD, BW). In SC-M1 cells,
berberine treatment had no effect on cell cycle progression while
low and high dose Paclitaxel treatment resulted in an apoptotic
peak and a G2/M phase arrested cell population. These results
were in accordance with our previous findings. However, it is
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Figure 3 The effect of Paclitaxel on cell viability of three cancer cell lines.
Paclitaxel treated cells (solid circle) for 24 h or 72 h. Cells pretreated with
32 mM berberine for 24 h (open circle) and then treated with 1 nM–1 mM
Paclitaxel or vehicle solvent, DMSO (0.1%), for an additional 24 or 72 h.
Each point represents mean ± s.e.m. from duplicated samples of three
separate experiments. *Indicates statistical difference at P < 0.05 using
ANOVA analysis and Tukey test
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high (BH; 0.1 mM) dose of Paclitaxel for another 24 h. C48 represents the cells that growth on normal condition for 48 h420 H-L Lin et al
British Journal of Cancer (1999) 81(3), 416–422 © 1999 Cancer Research Campaign
interesting that pretreatment with berberine blocked the Paclitaxel-
induced changes in cell cycle progression. No significant apop-
tosis and G2/M arrest was observed on low (BL) or high dose
(BH) Paclitaxel treatment groups. For COLO 205 cells, high dose
Paclitaxel treatment induced a significant G2/M phase arrest while
low dose Paclitaxel treatment has no significant effect on cell
cycle progression. Similarly, the Paclitaxel-induced cell cycle
effect was blocked by berberine-pretreatment.
Figure 5 shows the effect of berberine on Paclitaxel-induced
changes on morphology of OC2 (A-F) and SC-M1 cells (G-L).
Low (10 nM) or high (100 nM) dose of Paclitaxel induced OC2
cells to round up or produce membrane blebbing. Similar morpho-
logical alterations were found on high (100 nM) dose Paclitaxel-
treated SC-M1 cells. Berberine (32 mM) pretreatment for 24 h had
no significant effect on both OC2 (Figure 5D) and SC-M1 cells
(Figure 5J). In addition, pretreatment of OC2 and SC-M1 cells
with berberine completely blocked the low or high dose Paclitaxel
induced morphological changes.
In order to investigate whether MRP expression is also involved
in berberine-induced effect, we further examined the MRP expres-
sion in six cancer cell lines treated with berberine for 24 h. A slight
increase in the MRP expression was observed in berberine-treated
cells. Figure 6 shows that a 32 mM berberine treatment for 24 h
slightly increased the expression of MRP in OC2, SC-M1 and
COLO 205 cell lines.
DISCUSSION
Berberine had been documented to inhibit RNA, protein synthesis
and integrate into DNA to form complex. Previously, synergistic
cytotoxic effect of berberine (400 mM) and BCNU was found in
brain tumour cells (Zhang et al, 1990), whether berberine has
synergistic or antagonistic effect with other chemotherapeutic drug
is not clear.
In this study, we have found that the cell growth of berberine
(32 mM)-treated OC2, SC-M1 and COLO 205 cells was about 75%
of medium control (Table 1). Berberine not only induced pgp-170
expression on six cancer cell lines (Figure 1) but also elevated the
function of pgp-170 in these cancer cell lines (Figure 2). Nishino et
al had found that berberine inhibited the effect of 12-O-tetrade-
canoylphorbol-13-acetate (TPA)-induced responses (Nishino et al,
1986). In another study, the accumulation of TPA and TPA-induced
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Figure 5 The effect of Paclitaxel on cell morphology of OC2 (A, B, C, D, E, F) and SC-M1 (G, H, I, J, K, L). The cells were cultured on growth medium only
(A, G) or treated with low (B, H; 0.01 mM) or high (C, I; 0.1 mM) Paclitaxel for 24 h. On the other hand, the cells were incubated with berberine (32 mM) for 24 h
prior to replacement with fresh medium (D, J), low (E, K; 0.01 mM) or high (F, L; 0.1 mM) dose of Paclitaxel for additional 24 h. The microphotographs were taken
with an inverted microscope. The bar length represent approximately 66 mMBerberine-induced MDR1 expression reduced Paclitaxel responses in cancer cells 421
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protein kinase C activity in MDR-expressed KB cells are slightly
less than the MDR-negative KB cells (Cloud-Heflin et al, 1996).
The decreased TPA-induced responses may be due to, at least in
part, efflux of TPA by MDR transporter. Taken together, it seems
reasonable to conclude that berberine may have modulated MDR1
expression and leads to reduced drug uptake in tumour cells.
Although the mechanism underlying berberine elevated pgp-
170 expression is unclear but some reports indicated that cyclo-
heximide-induced protein synthesis inhibition elevated pgp-170
mRNA expression in HepG2 cells (Gant et al, 1992; Schuetz et al,
1995). The cycloheximide-induced polysome stabilization may
have contributed to the elevation of pgp-170 mRNA expression.
Berberine has been reported to inhibit protein synthesis in sarcoma
180 cells (Creasey, 1979), whether berberine stabilized polysome
and increased pgp-170 mRNA in these cancer cells is worthy of
further investigation.
In order to evaluate whether berberine-modulated pgp-170
function can interfere with chemotherapeutic drug response in
tumour cells, we assessed the Paclitaxel effect on cancer cells
pretreated with berberine. Berberine decreased Paclitaxel-induced
cytotoxicity in OC2, SC-M1, COLO 205 cells (Figure 3). In addi-
tion, berberine blocked high (0.1 mM) dose Paclitaxel-induced cell
cycle arrest at G2/M phase in OC2, SC-M1, COLO 205 and abro-
gated low (0.01 mM) dose Paclitaxel-elicited sub-G0/G1 apoptosis
in OC2, SC-M1 cells (Figure 4). Many studies documented that
combination of some chemotherapeutic drugs with Paclitaxel
decreased the response of Paclitaxel (Akutsu et al, 1995; Kano et
al, 1996a, 1996b). Most of these drugs arrested tumour cells at S
phase and the reduction of cells at G0/G1 or G2/M phases most
likely contributed to reduced responses to Paclitaxel. In a previous
study, we had reported that low dose of Paclitaxel induced apop-
tosis in gastric cancer cells (Chang et al, 1996) and this effect is
cycle-dependent (Lin et al, 1998). It is interesting that similar
effect was observed in OC2 cells. Berberine-induced cell cycle
arrest at G2/M phase and apoptosis in Balb/c 3T3 cells (Yang et al,
1996), however, the dose of berberine used (268–537 mM) was
much higher than we used (32 mM) in this study. In this study,
berberine treatment did not induce G2/M arrest and berberine
attenuated Paclitaxel-induced response was not the result of
berberine-elicited cycle arrest effect (Figure 4).
Clinically, the phase II clinical trial of Paclitaxel had been
performed on patients with oesophagus, gastric, hepatic or colon
cancer (Rowinsky et al, 1992; Einzig et al, 1993; Ajani et al, 1994;
Chao et al, 1998). The response rates were dependent upon cancer
types and administered drug concentration, but many reports indi-
cated that the low response rates were possibly associated with
MDR1 expression. In this study, we have found that berberine up-
regulated MDR1 expression in tumour cells (Figure 1) and the
pgp-170 was functional (Figure 2). Most importantly, pretreatment
of cancer cells with berberine blocked Paclitaxel-induced
responses (Figures 3–5). These results suggest that MDR1 may be
involved in low response rates of Paclitaxel. At present, no infor-
mation is available on clinical combination of berberine and
chemotherapeutic agents for treatment of cancer patients.
However, it is worthy to point out that for patients receiving
chemotherapy and simultaneously taking Chinese herbal medicine
containing berberine, reduced therapeutic effect may result from
up-regulation of MDR1.
Recently, another member of ABC family, MRP, had been
found with high levels of MRP1, cMOAT, MRP3 or MRP5
expression in stomach, liver, colon or salivary gland respectively
(Kool et al, 1997). In this study, we have found that berberine
treatment slightly enhanced MRP expression in OC2, SC-M1 and
COLO 205 cancer cells (Figure 6). It seems that the contribution
of this slightly increased MRP in reduction of rhodamine 123
retention may be limited. Nevertheless, our results are the first to
point out that there is antagonistic action between Paclitaxel and
berberine mediated, at least in part, by MDR1 expression.
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